BIONET (1784) Fundamentals 2026 — P/E 62.7x, Revenue Analysis | SniperIQ
BIONET (1784) is a TW-listed Healthcare company in Medical - Diagnostics & Research with a market capitalization of NT
BIONET's trailing twelve-month P/E ratio is 62.7x, with a price-to-book (P/B) of 0.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
BIONET runs a net profit margin of 3.0%, a gross margin of 55.2%, and an operating margin of -1.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
BIONET reported revenue of NT
BIONET offers a trailing dividend yield of about 2.3%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
BIONET carries a debt-to-equity ratio of 0.11x and a current ratio of 4.23x, with a market beta of 0.47. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For BIONET (1784) the key facts are: market cap NT
Get BIONET's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.